Nephros, Inc. (NEPH)

Nephros, Inc. reported strong financial results for fiscal year 2025, with a 33% year-over-year increase in net revenue and net income of $1.2 million. The company achieved its fourth consecutive profitable quarter in Q3 2025. However, Q4 2025 revenue growth decelerated, and net income fell, leading to a stock decline. Gross margin for Q4 2025 compressed due to tariffs on imports from Italy. The company expanded water safety capabilities with ASSE 12080 certified water management planning expertise in April 2026 and announced its expansion into Puerto Rico in February 2026. A renewed supply agreement with Medica extends through 2030, securing access to key membranes but committing Nephros to sizable volumes.

Specific details about the demand seasonality for Nephros, Inc.'s products and services are not provided in the available information. The company's business includes programmatic revenue from recurring filter use and emergency response sales related to compromised water events, suggesting a potentially steady base demand with spikes due to unforeseen water quality issues.

Nephros, Inc. is a water technology company that develops and sells water filtration and purification solutions for medical and commercial applications in the United States. The company's products include ultrafiltration products for medical use, real-time waterborne pathogen detection systems, and a second-generation hemodiafiltration system. For commercial markets, the company manufactures and sells water filters designed to enhance taste and odor, reduce biofilm and scale buildup, and remove contaminants from water systems.

Nephros, Inc. primarily operates in the United States. The company announced an expansion into the Puerto Rican market in February 2026, targeting healthcare, foodservice, and hospitality sectors, estimating a $10 million market opportunity.

Nephros is committed to improving water safety through innovative water filtration technology and water-quality education. The company expanded its water safety capabilities with ASSE 12080 Legionella Water Safety and Management Specialist Certification and launched the Nephros Water Institute in December 2025 to lead national water safety education. However, a material weakness in revenue recognition controls was cited in a March 2026 annual report, which could negatively affect governance and perceived risk.

The ownership structure of Nephros (NEPH) stock is a mix of institutional, retail, and individual investors. Approximately 45.37% to 47.31% of the company's stock is owned by Institutional Investors, 2.40% by Insiders, and a significant portion (around 50.28%) by Public Companies and Individual Investors. Major institutional owners include Wexford Capital Lp, Topline Capital Management, LLC, Vanguard Group Inc, Bard Associates Inc, Renaissance Technologies Llc, Geode Capital Management, Llc, Cambridge Investment Research Advisors, Inc., HighTower Advisors, LLC, Mesirow Financial Investment Management, Inc., and Essex Investment Management Co Llc. Lambda Investors LLC is noted as the largest individual Nephros shareholder, owning 44.37 million shares, representing 416.87% of the company, valued at approximately $126.91 million. Wexford Capital LP also holds a substantial amount, with 17.98 million shares.